|
|
Blood, 1 April 2008, Vol. 111, No. 7, pp. 3893-3895.
Prepublished online as a Blood First Edition Paper on January 30, 2008; DOI 10.1182/blood-2007-10-120329.
 Previous Article | Next Article 
Submitted October 25, 2007
Accepted January 28, 2008
The monoclonal anti-VLA4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans
Fabian Zohren*, Diamandis Toutzaris, Viola Klarner, Hans-Peter Hartung, Bernd Kieseier, and Rainer Haas
Department of Hematology, Oncology and Clinical Immunology, Heinrich Heine University, Duesseldorf, Germany
Department of Neurology, Heinrich Heine University, Duesseldorf, Germany
* Corresponding author; email: fabian.zohren{at}med.uni-duesseldorf.de.
We investigated the role of adhesion molecule VLA-4 in CD34+ blood stem cell mobilization. Therefore, we examined 20 patients with Multiple Sclerosis (MS) who were treated with the anti-VLA-4 antibody Natalizumab. Treated patients had received a median number of 4 natalizumab infusions (range 2-9). Blood samples were taken four weeks following the last infusion. With a median proportion of 7.6 CD34+ cells/µl (range 2.2-30.4) these patients had a significantly higher (p=0.003) amount of circulating CD34+ cells compared to 5 healthy volunteers (median 1.4, range 0.6-2.4) and 5 untreated MS patients (median 1.0, range 0.5-1.7) (p=0.001). Serial measurements in four patients receiving their first Natalizumab infusion showed a maximal significant increase in circulating CD34+ cells from 3.3/µl (range 1.6-4.8) to 10.4/µl (range 7.5-12.04) 72 hours following Natalizumab infusion (p=0.0005), representing pluripotent progenitors in colony-forming assays. These mobilizing ability of Natalizumab might be useful for patients with poor response to G-CSF based protocols.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Articles in Blood Online:
-
About multiple sclerosis, natalizumab, and CD34+ hematopoietic progenitors
- Carine Vuaillat, Géraldine Androdias, Nathalie Davoust, and Serge Nataf
Blood 2008 112: 208-209.
[Full Text]
[PDF]
-
Response: Natalizumab-induced mobilization of CD34+ hematopoietic progenitor cells
- Fabian Zohren
Blood 2008 112: 210.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
A. Y. H. Leung and Y.-L. Kwong
Haematopoietic stem cell transplantation: current concepts and novel therapeutic strategies
Br. Med. Bull.,
November 8, 2009;
(2009)
ldp040v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. O. Major
Reemergence of PML in Natalizumab-Treated Patients -- New Cases, Same Concerns
N. Engl. J. Med.,
September 10, 2009;
361(11):
1041 - 1043.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Soler, T. Chapman, L.-L. Yang, T. Wyant, R. Egan, and E. R. Fedyk
The Binding Specificity and Selective Antagonism of Vedolizumab, an Anti-{alpha}4{beta}7 Integrin Therapeutic Antibody in Development for Inflammatory Bowel Diseases
J. Pharmacol. Exp. Ther.,
September 1, 2009;
330(3):
864 - 875.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Ramirez, M. P. Rettig, G. L. Uy, E. Deych, M. S. Holt, J. K. Ritchey, and J. F. DiPersio
BIO5192, a small molecule inhibitor of VLA-4, mobilizes hematopoietic stem and progenitor cells
Blood,
August 13, 2009;
114(7):
1340 - 1343.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. N. Abboud
Another nail in the AML coffin
Blood,
June 11, 2009;
113(24):
6045 - 6046.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. R. Carson, A. M. Evens, E. A. Richey, T. M. Habermann, D. Focosi, J. F. Seymour, J. Laubach, S. D. Bawn, L. I. Gordon, J. N. Winter, et al.
Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project
Blood,
May 14, 2009;
113(20):
4834 - 4840.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. V. Kurtova, A. T. Tamayo, R. J. Ford, and J. A. Burger
Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting
Blood,
May 7, 2009;
113(19):
4604 - 4613.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. N. Hartmann, V. Grabovsky, W. Wang, P. Desch, G. Rubenzer, S. Wollner, I. Binsky, A. Vallon-Eberhard, A. Sapoznikov, M. Burger, et al.
Circulating B-Cell Chronic Lymphocytic Leukemia Cells Display Impaired Migration to Lymph Nodes and Bone Marrow
Cancer Res.,
April 1, 2009;
69(7):
3121 - 3130.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Krumbholz, I. Meinl, T. Kumpfel, R. Hohlfeld, and E. Meinl
Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis
Neurology,
October 21, 2008;
71(17):
1350 - 1354.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. Linker and B. C. Kieseier
Review: Innovative monoclonal antibody therapies in multiple sclerosis
Therapeutic Advances in Neurological Disorders,
July 1, 2008;
1(1):
33 - 42.
[Abstract]
[PDF]
|
|
|
|
|
|
|
C. Vuaillat, G. Androdias, N. Davoust, and S. Nataf
About multiple sclerosis, natalizumab, and CD34+ hematopoietic progenitors
Blood,
July 1, 2008;
112(1):
208 - 209.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Bonig, A. Wundes, and T. Papayannopoulou
Response: More about multiple sclerosis, natalizumab, and CD34+ hematopoietic progenitors
Blood,
July 1, 2008;
112(1):
209 - 210.
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Zohren
Response: Natalizumab-induced mobilization of CD34+ hematopoietic progenitor cells
Blood,
July 1, 2008;
112(1):
210 - 210.
[Full Text]
[PDF]
|
|
|
|
|
